Literature DB >> 28463661

Group B streptococcal bacteriuria during pregnancy as a risk factor for maternal intrapartum colonization: a prospective cohort study.

Mar Olga Pérez-Moreno1,2, Ester Picó-Plana2,3, Jesús Grande-Armas2,4, Mª José Centelles-Serrano2,1, Mercé Arasa-Subero5,6, Núria Colomé- Ochoa5, Members Of The Study Group Gessagte Led By Mo Pérez-Moreno7.   

Abstract

PURPOSE: Current evidence is inconclusive regarding the intrapartum administration of chemoprophylaxis, merely based on the presence of group B streptococcal (GBS) bacteriuria of any colony count, in the prevention of early-onset neonatal GBS infection. The aim of this study was to assess whether GBS bacteriuria is a risk factor for intrapartum colonization (IPC) regardless of urinary concentration or the results of late third-trimester rectovaginal screening cultures (RVSCs).
METHODOLOGY: Six hundred and eight pregnant women, with urine specimens cultured between May 2011 and May 2013, were enrolled in this prospective cohort study. RVSCs were available for 582 women and intrapartum rectovaginal cultures for 246.
RESULTS: The prevalence of GBS bacteriuria and positive RVSCs was 10.8 and 16.5 %, respectively. The frequency of IPC was 15.9 % (39/246). Sensitivity, specificity, positive and negative predictive values of urine culture and of RVSC in predicting GBS IPC were 41, 94.7, 59.3 and 89.5 %, and 76.9, 95.4, 76.9 and 95.4 %, respectively. GBS bacteriuria was significantly associated with IPC, overall [relative risk (RR) 5.6] and in women with negative RVSC (RR 8.5), with bacteriuria <104 c.f.u. ml-1 (RR 5.9) or when both circumstances coexisted (RR 8.9). The urinary colony count was <104 c.f.u. ml-1 in 13 of the 16 women with GBS bacteriuria and IPC.
CONCLUSION: GBS bacteriuria is a risk factor for IPC, irrespective of urinary GBS concentration or of colonization status at late gestation. Therefore, microbiology laboratories should search, and report, GBS of any colony count in urine from pregnant women, and not only in the presence of ≥104 c.f.u. ml-1 as the 2010 CDC guidelines recommend.

Entities:  

Mesh:

Year:  2017        PMID: 28463661     DOI: 10.1099/jmm.0.000465

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  Oral probiotics and the female urinary microbiome: a double-blinded randomized placebo-controlled trial.

Authors:  Birte J Wolff; Travis K Price; Cara J Joyce; Alan J Wolfe; Elizabeth R Mueller
Journal:  Int Urol Nephrol       Date:  2019-09-18       Impact factor: 2.370

Review 2.  Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children.

Authors:  Rachel E Hudson; Kathleen M Job; Casey L Sayre; Lubov V Krepkova; Catherine M Sherwin; Elena Y Enioutina
Journal:  Front Pharmacol       Date:  2022-04-27       Impact factor: 5.988

Review 3.  Group B Streptococcus (Streptococcus agalactiae).

Authors:  Vanessa N Raabe; Andi L Shane
Journal:  Microbiol Spectr       Date:  2019-03

Review 4.  Group B Streptococcal Maternal Colonization and Neonatal Disease: Molecular Mechanisms and Preventative Approaches.

Authors:  Kathryn A Patras; Victor Nizet
Journal:  Front Pediatr       Date:  2018-02-22       Impact factor: 3.418

5.  Comparison of qPCR and culture methods for group B Streptococcus colonization detection in pregnant women: evaluation of a new qPCR assay.

Authors:  J A Carrillo-Ávila; J Gutiérrez-Fernández; A I González-Espín; E García-Triviño; L G Giménez-Lirola
Journal:  BMC Infect Dis       Date:  2018-07-05       Impact factor: 3.090

6.  Group B streptococcal colonization in mothers and infants in western China: prevalences and risk factors.

Authors:  Jichang Chen; Jinjian Fu; Wei Du; Xin Liu; Chokechai Rongkavilit; Xuemei Huang; Yubi Wu; Yuanliu Wang; Eric McGrath
Journal:  BMC Infect Dis       Date:  2018-07-03       Impact factor: 3.090

7.  Asymptomatic GBS bacteriuria during antenatal visits: To treat or not to treat?

Authors:  Kelly D Rosenberger; Amy Seibert; Sara Hormig
Journal:  Nurse Pract       Date:  2020-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.